Grifols, S.A. (GIKLY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Grifols, S.A. (GIKLY) with AI Score 48/100 (Weak). Grifols, S. A. is a global healthcare company specializing in plasma-derived therapies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Grifols, S.A. (GIKLY) Healthcare & Pipeline Overview
Grifols, S.A. is a global leader in plasma-derived therapies, offering a diverse portfolio of products across its Bioscience, Hospital, Diagnostic, and Bio Supplies divisions. With a strong focus on innovation and a presence in key healthcare markets, Grifols serves public and private customers, contributing to the treatment of chronic and life-threatening diseases.
Investment Thesis
Grifols, S.A. presents a compelling investment case driven by its leading position in the plasma-derived therapies market and its diversified business model. The company's Bioscience division, which generates the majority of its revenue, benefits from increasing demand for plasma-derived products driven by an aging global population and expanding access to healthcare. Grifols' focus on innovation and strategic collaborations, such as its technology agreement with Mondragon, position it for long-term growth. With a P/E ratio of 15.77 and a dividend yield of 1.63%, Grifols offers a blend of value and income. However, investors may want to evaluate potential risks, including competition from other pharmaceutical companies and fluctuations in plasma supply and pricing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $14.61B reflects Grifols' significant presence in the healthcare sector.
- P/E ratio of 15.77 indicates a potentially attractive valuation compared to industry peers.
- Profit Margin of 5.3% demonstrates the company's ability to generate earnings from its operations.
- Gross Margin of 38.4% highlights Grifols' efficiency in managing its cost of goods sold.
- Dividend Yield of 1.63% provides investors with a steady income stream.
Competitors & Peers
Strengths
- Leading position in plasma-derived therapies
- Diversified product portfolio
- Global presence
- Strong research and development capabilities
Weaknesses
- Dependence on plasma supply
- Exposure to regulatory changes
- Competition from other pharmaceutical companies
- High debt levels
Catalysts
- Ongoing: Increasing demand for plasma-derived therapies due to an aging global population and expanding access to healthcare.
- Ongoing: Development of novel plasma-derived therapies for unmet medical needs.
- Ongoing: Strategic acquisitions to expand product portfolio and geographic reach.
Risks
- Potential: Fluctuations in plasma pricing and supply.
- Potential: Biosimilar competition from other pharmaceutical companies.
- Potential: Adverse regulatory actions affecting the company's products or operations.
- Ongoing: High debt levels.
Growth Opportunities
- Growth opportunity 1: Expansion in Emerging Markets: Grifols has the opportunity to expand its presence in emerging markets, where demand for plasma-derived therapies is growing rapidly due to increasing healthcare expenditure and improving access to treatment. By establishing partnerships with local healthcare providers and investing in infrastructure, Grifols can tap into these high-growth markets and increase its revenue. The emerging markets for plasma-derived therapies are projected to reach $15 billion by 2030.
- Growth opportunity 2: Development of Novel Therapies: Grifols can drive growth by investing in the research and development of novel plasma-derived therapies for unmet medical needs. By focusing on innovative solutions for chronic and rare diseases, Grifols can differentiate itself from competitors and capture a larger share of the market. The market for novel plasma-derived therapies is estimated to be worth $10 billion by 2028.
- Growth opportunity 3: Strategic Acquisitions: Grifols can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. By acquiring companies with complementary businesses, Grifols can strengthen its competitive position and accelerate its growth. The market for healthcare acquisitions is expected to remain active, with deal values reaching $500 billion in 2027.
- Growth opportunity 4: Increasing Plasma Collection: Securing a stable and growing supply of plasma is critical for Grifols' continued growth. The company can expand its plasma collection network by opening new donation centers and implementing innovative donor recruitment programs. By increasing its plasma collection capacity, Grifols can ensure a reliable supply of raw materials for its manufacturing operations. The global plasma collection market is projected to reach $40 billion by 2029.
- Growth opportunity 5: Diagnostic Solutions Expansion: Grifols can leverage its diagnostic division to develop and commercialize innovative diagnostic solutions for early disease detection and personalized medicine. By focusing on high-growth areas such as molecular diagnostics and point-of-care testing, Grifols can diversify its revenue streams and enhance its profitability. The global diagnostics market is expected to reach $120 billion by 2028.
Opportunities
- Expansion in emerging markets
- Development of novel therapies
- Strategic acquisitions
- Increasing plasma collection
Threats
- Fluctuations in plasma pricing
- Biosimilar competition
- Economic downturns
- Adverse regulatory actions
Competitive Advantages
- Proprietary plasma fractionation technology
- Extensive network of plasma donation centers
- Stringent regulatory approvals for its products
- Long-standing relationships with healthcare providers
- Diversified product portfolio
About GIKLY
Founded in 1940 and headquartered in Barcelona, Spain, Grifols, S.A. has evolved into a global healthcare company focused on the development, production, and commercialization of plasma-derived therapies, hospital products, and diagnostic solutions. The company operates through four primary divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies. The Bioscience division, the core of Grifols' business, researches, develops, manufactures, and markets plasma-derived medicines, including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. These therapies are crucial for treating patients with chronic, rare, prevalent, and life-threatening diseases. The Hospital division provides non-biological pharmaceutical products and medical supplies, including clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division focuses on researching, developing, producing, and commercializing diagnostic products used across the healthcare continuum. The Bio Supplies division offers biological materials for life-science research, clinical trials, and pharmaceutical and diagnostic product manufacturing. Grifols serves a diverse customer base, including public and private healthcare providers, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, care institutions, and national health systems.
What They Do
- Develops and manufactures plasma-derived therapies.
- Offers products for treating chronic, rare, and life-threatening diseases.
- Provides hospital products, including clinical nutrition and intravenous therapies.
- Develops and commercializes diagnostic products for disease screening and monitoring.
- Supplies biological materials for life-science research and pharmaceutical manufacturing.
- Serves healthcare providers, wholesalers, and national health systems globally.
Business Model
- Procures plasma through its network of donation centers.
- Manufactures plasma-derived products through its Bioscience division.
- Sells its products to healthcare providers and distributors.
- Generates revenue through the sale of plasma-derived therapies, hospital products, and diagnostic solutions.
Industry Context
Grifols operates within the global pharmaceutical industry, specifically focusing on plasma-derived therapies, hospital products, and diagnostic solutions. The market for plasma-derived therapies is experiencing growth due to the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and expanding healthcare access in emerging markets. The industry is competitive, with key players including ALPMF (Alphamab Oncology), ALPMY (Alphamab Oncology), BMXXY (Bioxcel Therapeutics), CHJTF (China Jo-Jo Drugstores), and FMCQF (Forma Therapeutics). Grifols differentiates itself through its integrated business model, which spans plasma collection, manufacturing, and commercialization.
Key Customers
- Public and private healthcare providers
- Wholesalers and distributors
- Group purchasing organizations
- Blood banks and hospitals
- National health systems
Financials
Chart & Info
Grifols, S.A. (GIKLY) stock price: Price data unavailable
Latest News
-
Grifols Plans IPO of U.S. Biopharma Business
Yahoo! Finance: GIKLY News · Mar 25, 2026
-
Grifols approves IPO of its US biopharma business
Yahoo! Finance: GIKLY News · Mar 24, 2026
-
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
Yahoo! Finance: GIKLY News · Mar 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GIKLY.
Price Targets
Wall Street price target analysis for GIKLY.
MoonshotScore
What does this score mean?
The MoonshotScore rates GIKLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Grifols Plans IPO of U.S. Biopharma Business
Grifols approves IPO of its US biopharma business
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
Leadership: Jose Ignacio Abia Buenache
Unknown
Information about Jose Ignacio Abia Buenache's background is not available in the provided context. Therefore, I am unable to provide details about his career history, education, or previous roles.
Track Record: Information about Jose Ignacio Abia Buenache's track record is not available in the provided context. Therefore, I am unable to provide details about his key achievements, strategic decisions, or company milestones under his leadership.
Grifols, S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. GIKLY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without as stringent SEC registration requirements. This allows U.S. investors to invest in Grifols, S.A. without directly dealing with foreign markets.
- Home Market Ticker: GIKL, Barcelona, ES
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: GIKL
GIKLY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Compared to listed companies, OTC Other stocks typically have higher risks due to less regulatory oversight and potentially less transparent operations. Investing in OTC Other stocks requires careful due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower liquidity and trading volume
- Higher bid-ask spreads
- Potential for price manipulation
- Less regulatory oversight
- Verify the company's registration and regulatory filings.
- Review the company's financials, if available.
- Assess the company's business model and competitive landscape.
- Research the company's management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any news or reports about the company from reputable sources.
- Established business operations in the healthcare sector
- Presence in multiple geographic markets
- Partnerships with reputable organizations
- Positive media coverage from reliable sources
- History of developing and commercializing pharmaceutical products
Common Questions About GIKLY
What does Grifols, S.A. do?
Grifols, S.A. is a global healthcare company that specializes in the development, production, and commercialization of plasma-derived therapies, hospital products, and diagnostic solutions. The company operates through its Bioscience, Hospital, Diagnostic, and Bio Supplies divisions. Its core business revolves around plasma-derived medicines, including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins, which are vital for treating patients with chronic, rare, and life-threatening diseases. Grifols also provides non-biological pharmaceutical products, medical supplies, and diagnostic tools to healthcare providers worldwide.
What do analysts say about GIKLY stock?
Analyst sentiment on GIKLY is pending AI analysis. Key valuation metrics to consider include the company's P/E ratio of 15.77 and its dividend yield of 1.63%. Growth considerations include the increasing demand for plasma-derived therapies and Grifols' expansion in emerging markets. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions.
What are the main risks for GIKLY?
Grifols faces several risks, including fluctuations in plasma pricing and supply, which can impact its manufacturing costs and profitability. The company also faces competition from biosimilars, which could erode its market share. Regulatory changes and adverse regulatory actions could also negatively affect Grifols' business. Additionally, the company's high debt levels pose a financial risk, particularly if interest rates rise or if the company experiences a decline in earnings.
What are the key factors to evaluate for GIKLY?
Grifols, S.A. (GIKLY) currently holds an AI score of 48/100, indicating low score. Key strength: Leading position in plasma-derived therapies. Primary risk to monitor: Potential: Fluctuations in plasma pricing and supply.. This is not financial advice.
How frequently does GIKLY data refresh on this page?
GIKLY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GIKLY's recent stock price performance?
Recent price movement in Grifols, S.A. (GIKLY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leading position in plasma-derived therapies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GIKLY overvalued or undervalued right now?
Determining whether Grifols, S.A. (GIKLY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GIKLY?
Before investing in Grifols, S.A. (GIKLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for GIKLY.